These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

152 related articles for article (PubMed ID: 26593241)

  • 1. Designing Irreversible Inhibitors--Worth the Effort?
    González-Bello C
    ChemMedChem; 2016 Jan; 11(1):22-30. PubMed ID: 26593241
    [TBL] [Abstract][Full Text] [Related]  

  • 2. IRAK-4 inhibitors. Part 1: a series of amides.
    Buckley GM; Gowers L; Higueruelo AP; Jenkins K; Mack SR; Morgan T; Parry DM; Pitt WR; Rausch O; Richard MD; Sabin V; Fraser JL
    Bioorg Med Chem Lett; 2008 Jun; 18(11):3211-4. PubMed ID: 18474425
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Covalent inhibition of the lymphoid tyrosine phosphatase.
    Ahmed VF; Bottini N; Barrios AM
    ChemMedChem; 2014 Feb; 9(2):296-9. PubMed ID: 24403103
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Rational design of new bifunctional inhibitors of type II dehydroquinase.
    Toscano MD; Stewart KA; Coggins JR; Lapthorn AJ; Abell C
    Org Biomol Chem; 2005 Sep; 3(17):3102-4. PubMed ID: 16106291
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Gaining insight into the catalysis by GH20 lacto-N-biosidase using small molecule inhibitors and structural analysis.
    Hattie M; Ito T; Debowski AW; Arakawa T; Katayama T; Yamamoto K; Fushinobu S; Stubbs KA
    Chem Commun (Camb); 2015 Oct; 51(81):15008-11. PubMed ID: 26312778
    [TBL] [Abstract][Full Text] [Related]  

  • 6. "Click" synthesis of small-molecule inhibitors targeting caspases.
    Ng SL; Yang PY; Chen KY; Srinivasan R; Yao SQ
    Org Biomol Chem; 2008 Mar; 6(5):844-7. PubMed ID: 18292873
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Rational design, synthesis, and evaluation of nanomolar type II dehydroquinase inhibitors.
    Payne RJ; Peyrot F; Kerbarh O; Abell AD; Abell C
    ChemMedChem; 2007 Jul; 2(7):1015-29. PubMed ID: 17487900
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Antibiotic resistance by enzyme inactivation: from mechanisms to solutions.
    De Pascale G; Wright GD
    Chembiochem; 2010 Jul; 11(10):1325-34. PubMed ID: 20564281
    [No Abstract]   [Full Text] [Related]  

  • 9. Unexpected small molecules as novel SIRT2 suicide inhibitors.
    Chen X; Zou Y; Wang J; Cao Z; Liu J; Li Y; Zhao Y; He B
    Bioorg Med Chem; 2020 Mar; 28(6):115353. PubMed ID: 32061485
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Design, synthesis and biological evaluation of small molecules as potent glucosidase inhibitors.
    Hati S; Madurkar SM; Bathula C; Thulluri C; Agarwal R; Siddiqui FA; Dangi P; Adepally U; Singh A; Singh S; Sen S
    Eur J Med Chem; 2015 Jul; 100():188-96. PubMed ID: 26087029
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Massive screening yields novel and selective Trypanosoma cruzi triosephosphate isomerase dimer-interface-irreversible inhibitors with anti-trypanosomal activity.
    Alvarez G; Aguirre-López B; Varela J; Cabrera M; Merlino A; López GV; Lavaggi ML; Porcal W; Di Maio R; González M; Cerecetto H; Cabrera N; Pérez-Montfort R; de Gómez-Puyou MT; Gómez-Puyou A
    Eur J Med Chem; 2010 Dec; 45(12):5767-72. PubMed ID: 20889239
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Selective inhibitors of protein methyltransferases.
    Kaniskan HÜ; Konze KD; Jin J
    J Med Chem; 2015 Feb; 58(4):1596-629. PubMed ID: 25406853
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Structure-based design of targeted covalent inhibitors.
    Lonsdale R; Ward RA
    Chem Soc Rev; 2018 Jun; 47(11):3816-3830. PubMed ID: 29620097
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The design of covalent allosteric drugs.
    Nussinov R; Tsai CJ
    Annu Rev Pharmacol Toxicol; 2015; 55():249-67. PubMed ID: 25149918
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Irreversible inhibition of dihydrodipicolinate synthase by 4-oxo-heptenedioic acid analogues.
    Boughton BA; Griffin MD; O'Donnell PA; Dobson RC; Perugini MA; Gerrard JA; Hutton CA
    Bioorg Med Chem; 2008 Dec; 16(23):9975-83. PubMed ID: 18977662
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Nox Inhibitors & Therapies: Rational Design of Peptidic and Small Molecule Inhibitors.
    Cifuentes-Pagano ME; Meijles DN; Pagano PJ
    Curr Pharm Des; 2015; 21(41):6023-35. PubMed ID: 26510437
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Design, synthesis and characterization of dual inhibitors against new targets FabG4 and HtdX of Mycobacterium tuberculosis.
    Banerjee DR; Biswas R; Das AK; Basak A
    Eur J Med Chem; 2015 Jul; 100():223-34. PubMed ID: 26092447
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Progress in type II dehydroquinase inhibitors: from concept to practice.
    González-Bello C; Castedo L
    Med Res Rev; 2007 Mar; 27(2):177-208. PubMed ID: 17004270
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Identification of small molecule sphingomyelin synthase inhibitors.
    Deng X; Lin F; Zhang Y; Li Y; Zhou L; Lou B; Li Y; Dong J; Ding T; Jiang X; Wang R; Ye D
    Eur J Med Chem; 2014 Feb; 73():1-7. PubMed ID: 24374347
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Heterocyclic inhibitors of dihydrodipicolinate synthase are not competitive.
    Turner JJ; Gerrard JA; Hutton CA
    Bioorg Med Chem; 2005 Mar; 13(6):2133-40. PubMed ID: 15727866
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.